Ingrid Delaet Sells 273 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 273 shares of the stock in a transaction on Monday, May 6th. The stock was sold at an average price of $140.55, for a total value of $38,370.15. Following the completion of the transaction, the insider now owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ingrid Delaet also recently made the following trade(s):

• On Thursday, March 21st, Ingrid Delaet sold 5,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $145.06, for a total transaction of $725,300.00.
• On Monday, March 11th, Ingrid Delaet sold 200 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00.
• On Friday, March 8th, Ingrid Delaet sold 1,800 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $140.03, for a total transaction of $252,054.00.
• On Thursday, February 29th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $135.51, for a total value of $36,994.23.

Neurocrine Biosciences Stock Up 0.5 %

NBIX opened at $139.66 on Friday. The company has a 50 day moving average of $137.91 and a two-hundred day moving average of $129.58. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The company has a market cap of $14.05 billion, a P/E ratio of 38.47 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.88 EPS. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.78 earnings per share for the current year.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently modified their holdings of the stock. Cumberland Partners Ltd acquired a new position in Neurocrine Biosciences during the 1st quarter worth approximately $414,000. Twin Tree Management LP lifted its position in shares of Neurocrine Biosciences by 59.4% during the first quarter. Twin Tree Management LP now owns 19,147 shares of the company’s stock worth $2,641,000 after purchasing an additional 7,136 shares in the last quarter. RFP Financial Group LLC boosted its stake in shares of Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock valued at $26,000 after purchasing an additional 149 shares during the period. Blair William & Co. IL grew its holdings in Neurocrine Biosciences by 5.9% during the 1st quarter. Blair William & Co. IL now owns 8,599 shares of the company’s stock valued at $1,186,000 after purchasing an additional 481 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Neurocrine Biosciences by 34.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 55,194 shares of the company’s stock worth $7,612,000 after buying an additional 14,015 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NBIX. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Citigroup increased their price target on shares of Neurocrine Biosciences from $140.00 to $150.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd. Barclays lifted their price objective on Neurocrine Biosciences from $150.00 to $169.00 and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Finally, The Goldman Sachs Group raised their price target on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Six analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $147.88.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.